AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24572995
Drug: Prilocaine-lidocaine (PLA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prilocaine-lidocaine (PLA) cream applied to the glans penis for 10 min before measurements
Trial: 24572995
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied to the glans penis for 10 min before measurements
Trial: 22498045
Drug: Morphine (routine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (routine intravenous narcotics)
Trial: 20430594
Drug: Low Lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Lithium levels (<0.6 mmol/L)
Trial: 20430594
Drug: Medium Lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium Lithium levels (0.6-0.79 mmol/L)
Trial: 20430594
Drug: Low Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low Olanzapine doses (<10mg/day)
Trial: 20430594
Drug: Higher Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher Olanzapine doses (10-20mg/day)
Trial: 16236142
Drug: Intravenous corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous corticosteroid therapy (500 mg intravenous methylprednisolone daily)
Trial: 16236142
Drug: Oral corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroid therapy (1 mg/kg oral prednisolone daily)
Trial: 16236142
Drug: Intravenous corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous corticosteroid therapy
Trial: 10207780
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg, Amoxycillin 1.0 g, Metronidazole 400 mg (12 h post-treatment)
Trial: 8563457
Drug: Midodrine (alpha-receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine (alpha-receptor agonist)
Trial: 1122828
Drug: Vincristine, chlormethine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine, chlormethine, procarbazine and prednisone (protocol H2‐65) for six months, followed by monthly vinblastine injections.
Trial: 1122828
Drug: Vincristine, chlormethine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine, chlormethine, procarbazine and prednisone (protocol H2‐65) with reinduction treatment.
Trial: 28478481
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ω-3 fatty acids and nano-curcumin
Trial: 21275850
Drug: RAC (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAC (7.5 mg over 1 hour)
Trial: 21275850
Drug: LEV (3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEV (3.75 mg over 1 hour)
Trial: 21458532
Drug: Cognitive Remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Remediation Therapy (CRT), 40 sessions
Trial: 15136378
Drug: Budesonide 200
RxNorm normalized name: budesonide 200 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 200 microg (400 microg/d) plus Zafirlukast 20 mg bid
Trial: 11091168
Drug: Low-dose citrate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose citrate anticoagulation (60 IU heparin/kg body weight as initial bolus; 1:40 ACD‐A: blood as perfusion)
Trial: 11091168
Drug: Standard anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anticoagulation regimen (20 IU heparin/kg bolus; 1:20 ACD‐A as perfusion)
Trial: 9135702
Drug: Pyridostigmine (PD,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (PD, 120 mg, orally)
Trial: 3524842
Drug: Nalbuphine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine (10 mg IV)
Trial: 7541310
Drug: Meperidine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (50 mg IV)
Trial: 28641022
Drug: Fitnox (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fitnox (250 mg capsule as single dose)
Trial: 22498110
Drug: GSK573719 once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK573719 once-daily doses (62.5-1000 μg)
Trial: 22498110
Drug: GSK573719 twice-daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GSK573719 twice-daily doses (62.5-250 μg)
Trial: 20054739
Drug: Quercetin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin supplementation (1000 mg x day(‐1))
Trial: 12427189
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution administered prior to endotracheal suctioning
Trial: 12427189
Drug: Suctioning without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suctioning without saline solution
Trial: 10868559
Drug: E2 1
RxNorm normalized name: PGE2 10 MG Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 1 mg/NGM 90 microg
Trial: 10617250
Drug: E2 1
RxNorm normalized name: PGE2 10 MG Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 1 mg/NGM 30 microg
Trial: 10617250
Drug: E2 1
RxNorm normalized name: PGE2 10 MG Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 1 mg
Trial: 2233115
Drug: Nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 10 mg three times daily
Trial: 26858331
Drug: High-Dose Interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Dose Interferon Alfa-2b (HDI)
Trial: 31299242
Drug: Intensity modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensity modulated radiation therapy
Trial: 31299242
Drug: 3-dimensional chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dimensional chemoradiation therapy
Trial: 25829048
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate (40 mg.kg(‐1))
Trial: 24043677
Drug: 23 to
RxNorm normalized name: vehicle base no.23 TOPICAL CREAM (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23 to 32 mm Hg (moderate) compression stocking treatment
Trial: 24043677
Drug: 34 to
RxNorm normalized name: cream base no.134 TOPICAL CREAM (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 34 to 46 mm Hg (high) compression stocking treatment
Trial: 21642014
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 400 mg subcutaneously at weeks 0, 2, and 4
Trial: 19806184
Drug: 3 dose
RxNorm normalized name: Hep A, ped/adol, 3 dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 dose schedules
Trial: 19806184
Drug: RTS,S/AS01(E) and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01(E) and rabies vaccine
Trial: 15067028
Drug: FU-based therapy
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FU-based therapy
Trial: 11742269
Drug: Nasal Steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal Steroid (NS) - budesonide 400 microg daily
Trial: 9338418
Drug: Haloperidol (Seranace,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (Seranace, 0.05 mg/kg)
Trial: 7509325
Drug: Cilazapril 2.5-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 2.5-5 mg once daily
Trial: 7509325
Drug: Hydrochlorothiazide 25-50
RxNorm normalized name: captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25-50 mg once daily
Trial: 20962899
Drug: Amiloride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride (10 mg)
Trial: 18947475
Drug: Rhu‐EPO treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhu‐EPO treatment (250 IU/kg, 3 times weekly for 4 weeks)
Trial: 18947475
Drug: Rhu‐EPO treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhu‐EPO treatment
Trial: 15714171
Drug: Low-dose tacrolimus
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tacrolimus (0.075 mg/kg/day)
Trial: 15714171
Drug: High-dose tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tacrolimus (0.15 mg/kg/day)
Trial: 1290620
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg, 100 mg, 150 mg
Trial: 1290620
Drug: Losartan 10
RxNorm normalized name: LOSARTAN 100MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 10 mg, 25 mg
Trial: 1290620
Drug: Losartan (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (various doses)
Trial: 30860000
Drug: Amphetamine extended-release
RxNorm normalized name: amphetamine Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine extended-release oral suspension (AMPH EROS)
Trial: 26198386
Drug: 5-week group-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-week group-based multidisciplinary programme of task-oriented exercises integrated with cognitive behavioural therapy
Trial: 24460589
Drug: Acidulated phosphate
RxNorm normalized name: Acidulated Phosphate Fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acidulated phosphate fluoride gel
Trial: 24460589
Drug: Antibacterial bonding
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibacterial bonding agent (Clearfil Protect Bond)
Trial: 9459240
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of propofol (n = 17)
Trial: 9459240
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of placebo (n = 12)
Trial: 2561144
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg benazepril orally once a day for 2 days
Trial: 30183398
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (VC) supplementation 300 mg per day for 6 months
Trial: 26062187
Drug: Captopril tablets
RxNorm normalized name: Captopril Tablets
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril tablets (12.5 mg, twice a day)
Trial: 26062187
Drug: Captopril tablets
RxNorm normalized name: Captopril Tablets
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril tablets
Trial: 21601287
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Bupropion + Escitalopram or Venlafaxine + Mirtazapine)
Trial: 21601287
Drug: Monotherapy (Escitalopram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (Escitalopram + placebo)
Trial: 14706487
Drug: Methylphenidate (extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (extended-release version)
Trial: 11990444
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of EMD and BDX
Trial: 9650731
Drug: Allithiamin and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allithiamin and pantethine supplementation (1 g of allithiamin and 1.8 g of a 55%/45% pantethine/pantothenic acid compound)
Trial: 7573298
Drug: 0.05 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/day estradiol patch
Trial: 7573298
Drug: 0.1 mg/day
RxNorm normalized name: Lyllana 0.1 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/day estradiol patch
Trial: 7663539
Drug: 0.625 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg/day oral conjugated estrogens (Premarin)
Trial: 2486587
Drug: Warm intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm intravenous crystalloid and prep solutions, extra body covering (Group 2)
Trial: 2486587
Drug: No warm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No warm intravenous crystalloid or extra body covering (Group 1)
Trial: 31625262
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary intervention (PCI) with contemporary drug-eluting stents (DES)
Trial: 28826895
Drug: Preoperative β-blocker
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative β-blocker use
Trial: 23507424
Drug: Atorvastatin 10mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 10MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10mg daily for four weeks
Trial: 23507424
Drug: Atorvastatin 40mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 40MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40mg for four weeks
Trial: 23507424
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of atorvastatin 40mg / ezetimibe 10mg for four weeks
Trial: 23507424
Drug: Atorvastatin 40mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 40MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40mg alone
Trial: 28681986
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg)
Trial: 21325466
Drug: Rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (4 mg)
Trial: 15482765
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of metformin and rosiglitazone
Trial: 11737418
Drug: Transdermal DHT
RxNorm normalized name: stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal DHT and one subdermal LNG implant
Trial: 11737418
Drug: Transdermal DHT
RxNorm normalized name: stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal DHT and two subdermal LNG implants
Trial: 11737418
Drug: Transdermal DHT
RxNorm normalized name: stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal DHT and four subdermal LNG implants
Trial: 11737418
Drug: Transdermal DHT
RxNorm normalized name: stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal DHT and oral LNG
Trial: 11737418
Drug: Transdermal DHT
RxNorm normalized name: stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal DHT only
Trial: 9050428
Drug: Group cognitive-behavioral
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive-behavioral treatment of anxiety
Trial: 7937352
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide (ANP) infusion (4 pmol.kg‐1.min‐1)
Trial: 31969108
Drug: Remote model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote model intervention with at-home, parent-delivered intervention and weekly video conferencing with interventionists.
Trial: 29878280
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of L-DOPA
Trial: 28973211
Drug: IVIg (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIg (0.5 g/kg of body weight)
Trial: 28973211
Drug: IVIg (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIg (2 infusions) in open extension
Trial: 16441945
Drug: 600 g
RxNorm normalized name: PETROLATUM 600 g in 1000 g TOPICAL OINTMENT [EltaMD Laser Balm]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 g fruit and vegetables/day
Trial: 12829681
Drug: Primary systemic
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary systemic therapy (PST)
Trial: 10623700
Drug: Cisplatin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (100 mg/m(2))
Trial: 10623700
Drug: Paclitaxel (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (200 mg/m(2) 24-hour infusion)
Trial: 10623700
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of paclitaxel (135 mg/m(2)) followed by cisplatin (75 mg/m(2))
Trial: 1489290
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg + Dipyridamole 300 mg
Trial: 2418296
Drug: Nicorandil (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (60 mg s.l.)
Trial: 2418296
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN; 20 mg s.l.)
Trial: 2418296
Drug: Dihydralazine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydralazine (10 mg i.v.)
Trial: 31455312
Drug: Hand therapy
RxNorm normalized name: Octinoxate 3.00 mL in 75 mL / Avobenzone 1.5 mL in 75 mL TOPICAL CREAM [Botanics Daily Hand Therapy Sunscreen SPF 10]
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hand therapy (includes oedema and scar management, splinting, movement exercises, and practice of everyday activities)
Trial: 29065098
Drug: Sodium nitrite
RxNorm normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium nitrite (NaNO2) infusion at 240 μg/kg/h for 2 hours
Trial: 27739087
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline infusion
Trial: 27880811
Drug: Domperidone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (0.5 mg/kg)
Trial: 25092547
Drug: 8 mg/day
RxNorm normalized name: Neupro 8 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg/day dexamethasone for 28 days followed by a 2-week taper (enhanced)
Trial: 25092547
Drug: 6 mg/day
RxNorm normalized name: EMSAM 6 MG/Day 24HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/day dexamethasone for 10 days (conventional)
Trial: 20724711
Drug: Normothermia (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normothermia (standard treatment)
Trial: 7710563
Drug: Diltiazem (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (180 to 360 mg/day)
Trial: 2278366
Drug: APA (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APA (acute parenteral alimentation)
Trial: 2278366
Drug: Control (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0.9% NaCl solution)
Trial: 364003
Drug: 1% Chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% Chlorhexidine gel
Trial: 21323176
Drug: DTPa-IPV/Hib vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa-IPV/Hib vaccine
Trial: 21323176
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of DTPa-IPV/Hib
Trial: 14531817
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low protein diet (VLPD) group (0.3 g/kg body weight/day)
Trial: 14531817
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein diet (LPD) group (0.6 g/kg body weight/day)
Trial: 9390977
Drug: 1 G
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 G
Trial: 9390977
Drug: Approximately 1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 1.6 G
Trial: 9390977
Drug: 1 G
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 G and approximately 1.6 G
Trial: 8150902
Drug: Subcutaneous goserelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous goserelin (3.6 mg)
Trial: 8150902
Drug: Intranasal buserelin
RxNorm normalized name: buserelin
DrugBank: Buserelin (DB06719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal buserelin acetate (200 micrograms; 6 times/day)
Trial: 30294848
Drug: Gastrografin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrografin (100 mL administered through nasointestinal tube once daily for six consecutive days)
Trial: 30294848
Drug: Enemas (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enemas (administered once daily for six consecutive days)
Trial: 24660675
Drug: Weekly dynamic
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly dynamic psychotherapy with relationship work
Trial: 24660675
Drug: Weekly dynamic
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly dynamic psychotherapy without relationship work
Trial: 22113935
Drug: Screening tool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening tool for osteoporotic vertebral fractures (VFs) administered by a nurse in primary care.
Trial: 19107626
Drug: Polydextrose (PDX)
RxNorm normalized name: Polydextrose
DrugBank: Polydextrose (DB14836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polydextrose (PDX) supplementation (8 g/day)